You are here:

dronedarone (Multaq)

Advice

Following a full submission:

dronedarone (Multaq®) is accepted for restricted use within NHS Scotland.

Indication under review: in adult clinically stable patients with a history of, or current non permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate.

SMC restriction: for the prevention of recurrence of AF in patients in whom beta-blockers, class 1c drugs or amiodarone are contra-indicated, ineffective or not tolerated. Treatment should be initiated on specialist advice only.

Dronedarone appears less effective than amiodarone in reducing atrial fibrillation recurrence but has the potential for improved tolerability compared to comparator medicines. 

Drug Details

Drug Name: dronedarone (Multaq)
SMC Drug ID: 636/10
Manufacturer: Sanofi-Aventis
Indication: For the treatment of atrial fibrillation
BNF Category:
Sub Category: 2.3 Anti-arrhythmic drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 13 September 2010

Back